Harms of TNF inhibitors in rheumatic diseases: A focused review of the literature

Academic Article


  • A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use. © 2013 Future Medicine Ltd.
  • Authors

    Published In

  • Immunotherapy  Journal
  • Digital Object Identifier (doi)

    Author List

  • Jain A; Singh JA
  • Start Page

  • 265
  • End Page

  • 299
  • Volume

  • 5
  • Issue

  • 3